0000899243-20-028422.txt : 20201015 0000899243-20-028422.hdr.sgml : 20201015 20201015201443 ACCESSION NUMBER: 0000899243-20-028422 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200826 FILED AS OF DATE: 20201015 DATE AS OF CHANGE: 20201015 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Haddock Jason CENTRAL INDEX KEY: 0001680628 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39615 FILM NUMBER: 201242521 MAIL ADDRESS: STREET 1: C/O ARRAY BIOPHARMA INC., 3200 WALNUT ST CITY: BOULDER STATE: CO ZIP: 80301 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Codiak BioSciences, Inc. CENTRAL INDEX KEY: 0001659352 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: C/O ARCH VENTURE PARTNERS STREET 2: 999 THIRD AVENUE, SUITE 3400 CITY: SEATTLE STATE: WA ZIP: 98104 BUSINESS PHONE: 857-400-4222 MAIL ADDRESS: STREET 1: C/O ARCH VENTURE PARTNERS STREET 2: 999 THIRD AVENUE, SUITE 3400 CITY: SEATTLE STATE: WA ZIP: 98104 FORMER COMPANY: FORMER CONFORMED NAME: Codiak Biosciences, Inc. DATE OF NAME CHANGE: 20151125 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-08-26 0 0001659352 Codiak BioSciences, Inc. CDAK 0001680628 Haddock Jason C/O CODIAK BIOSCIENCES, INC. 35 CAMBRIDGEPARK DRIVE, SUITE 500 CAMBRIDGE MA 02140 1 0 0 0 Stock Option (Right to Buy) 19.47 2020-08-26 4 A 0 31981 0.00 A 2030-08-25 Common Stock 31981 31981 D Stock Option (Right to Buy) 15.00 2020-10-13 4 A 0 10000 0.00 A 2030-10-12 Common Stock 10000 10000 D On October 2, 2020, the Issuer completed a 1-for-7.187 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to the Reverse Stock Split. This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. 25% of this option shall vest and become exercisable on August 26, 2021, with the remainder vesting in 12 equal quarterly installments thereafter. This option shall vest in full upon the earlier to occur of (i) October 13, 2021, and (ii) the next annual meeting of the Issuer's stockholders. /s/ Yalonda Howze by Power of Attorney for Jason Haddock 2020-10-15